Feuchtwang Ilan reported grant involving 25,745 derivative units of Cytek Biosciences, Inc. at $0.00 for $0 on Nov 9, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
25,745Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
25,745Direct
Trade date
Nov 9, 2026Grant
Filed
Nov 12, 2026, 8:43 PM ET4-day reporting delay
Accession
0002141966-26-000004Code A · Transaction 400111
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CTKB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CTKB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −9.2%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on November 18, 2027; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, and 3/48 of the RSUs vesting on November 18, 2028 and each November 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan (the "2021 Plan"))).